Moderna lifts 2026 outlook after quarterly revenue tops estimates
The company now expects revenue growth of 15% to 25%, citing momentum in newer products and stronger third-quarter results.
Makkler Newsroom · Nov 6, 03:13 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $162.96 (+10.3%)
Prices may be delayed and are for informational purposes only - not investment advice.
The company now expects revenue growth of 15% to 25%, citing momentum in newer products and stronger third-quarter results.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.